PEAK

NCT00819780 📎

Regimen

Experimental
Panitumumab + mFOLFOX6
Control
Bevacizumab + mFOLFOX6

Population

KRAS wild-type (extended to pan-RAS wild-type) metastatic CRC, 1L, previously untreated.

Key finding

1L mCRC KRAS-wt exon 2: mPFS panitumumab 10.9 vs bev 10.1 mo (HR 0.87, 95% CI 0.65-1.17, NS); mOS 34.2 vs 24.3 mo (HR 0.62, 95% CI 0.44-0.89, p=0.009); RAS-wt (pan-RAS) subgroup: mOS 41.3 vs 28.9 mo (HR 0.58, p=0.058); PFS NS but OS favors panitumumab in RAS-wt

Source: PMID 24687833

Timeline

    Guideline citations

    • NCCN Colon (p.27)
    • NCCN Rectal (p.89)